AD/PD 2024 | Tau-targeted therapy landscape in Alzheimer’s disease

Bengt Winblad, MD, PhD, Karolinska Institutet, Solna, Sweden, discusses his thoughts on the importance of combined therapies targeting amyloid- and tau-pathology in treating Alzheimer’s disease. He also discusses recent advances in the tau-targeted therapy research landscape in Europe, including the use of active immunotherapy. Prof. Wingblad highlights an example treatment where patients are injected with part of a tau molecule, thereby developing their own antibodies, making this cheaper and more efficient than passive therapy. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.